ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 1 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2023. The put-call ratio across all filers is - and the average weighting 14.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $202 | +27.0% | 206,156 | +80.4% | 0.00% | – |
| Q2 2023 | $159 | -100.0% | 114,300 | -60.1% | 0.00% | -100.0% |
| Q3 2022 | $1,921,000 | -21.6% | 286,700 | -25.6% | 0.00% | 0.0% |
| Q2 2022 | $2,451,000 | +25.1% | 385,300 | -8.7% | 0.00% | +50.0% |
| Q1 2022 | $1,959,000 | -62.3% | 422,200 | +197.5% | 0.00% | -50.0% |
| Q3 2019 | $5,202,000 | -52.9% | 141,900 | -40.3% | 0.00% | -60.0% |
| Q2 2019 | $11,049,000 | +40.7% | 237,500 | +21.4% | 0.01% | +42.9% |
| Q1 2019 | $7,853,000 | +854.2% | 195,595 | +992.7% | 0.01% | +600.0% |
| Q4 2018 | $823,000 | +13.2% | 17,900 | +23.4% | 0.00% | 0.0% |
| Q3 2017 | $727,000 | -83.5% | 14,500 | -95.5% | 0.00% | -87.5% |
| Q3 2016 | $4,415,000 | +142.6% | 318,800 | +196.3% | 0.01% | +166.7% |
| Q1 2016 | $1,820,000 | -77.4% | 107,600 | -70.2% | 0.00% | -83.3% |
| Q4 2015 | $8,040,000 | – | 361,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |